biostudies-literatureChhabra MHospital for Sick Children Foundation and the Canadian Institutes of Health Researche0290185https://www.ebi.ac.uk/biostudies/studies/S-EPMC11414974biostudies-literatureUnknown19(9)<h4>Introduction</h4>Cannabis products have been used in the management of headaches in adults and may play a role in pediatric chronic pain. Canadian pediatricians report increasing use of cannabis for the management of chronic headaches, despite no well-controlled studies to inform its dosing, safety, and effectiveness. The aim of our clinical trial is to determine the dosing and safety of a Cannabidiol (CBD)-enriched Cannabis Herbal Extract (CHE) for the treatment of chronic headaches in adolescents.<h4>Methods and analysis</h4>Youth, parents, and an expert steering committee co-designed this tolerability study. Twenty adolescents (aged 14 to 17 years), with a chronic migraine diagnosis for more than 6 months that has not responded to other therapies will be enrolled into an open label,PloS oneA multi-centre, tolerability study of a cannabidiol-enriched Cannabis Herbal Extract for chronic headaches in adolescents: The CAN-CHA protocol.PMC11414974N120-1028Penz EDrogemoller BIWeil AGLowthian TRobson-MacKay AGordon SChhabra MAlcorn JFinley GABalshaw RPohl DHuntsman RJStewart BAlidina ZIrwin SLXie WBlackman SBirnie KABoerner KEMbabaali SLewis ECTsang VWLSell EChesick-Gordis MKelly LEZaslawski ZWright GEBOberlander TFfalseA multi-centre, tolerability study of a cannabidiol-enriched Cannabis Herbal Extract for chronic headaches in adolescents: The CAN-CHA protocol.<h4>Introduction</h4>Cannabis products have been used in the management of headaches in adults and may play a role in pediatric chronic pain. Canadian pediatricians report increasing use of cannabis for the management of chronic headaches, despite no well-controlled studies to inform its dosing, safety, and effectiveness. The aim of our clinical trial is to determine the dosing and safety of a Cannabidiol (CBD)-enriched Cannabis Herbal Extract (CHE) for the treatment of chronic headaches in adolescents.<h4>Methods and analysis</h4>Youth, parents, and an expert steering committee co-designed this tolerability study. Twenty adolescents (aged 14 to 17 years), with a chronic migraine diagnosis for more than 6 months that has not responded to other therapies will be enrolled into an open label,2024-01-01T00:00:00Z20242026-06-02T09:21:05.086Z2025-04-04T12:54:00.094ZS-EPMC114149743930298210.1371/journal.pone.0290185